EIM
RARX

Essex Investment Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Essex Investment Management’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-34,453
Closed -$623K – 558
2018
Q3 		$623K Buy
+34,453
New +$408K 0.07% 277

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MMPI
Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Essex Investment Management's RARX Position: Q4 2018 in Review

Essex Investment Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2018, closing a stake of 34,453 shares — an estimated $623K sold.

Essex Investment Management first reported a position in RARX in Q3 2018 and held it in 1 quarter. The position peaked at $623K in Q3 2018. 94 funds tracked by Wall St. Rank hold RARX as of Q4 2018.

  • Essex Investment Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Essex Investment Management sold 34,453 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $623K.
  • Essex Investment Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Essex Investment Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $623K in Q3 2018.
  • 94 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Essex Investment Management's 13F filing for Q4 2018, filed 6 Feb 2019.